GSK Advair patent re-issuance
GlaxoSmithKline will apply for re-issuance of Advair patent no. 5,270,305, which expires in September 2010. The decision "follows an internal review which concluded that the language in the patent may not accurately describe all of the circumstances of the invention and may not claim the invention as precisely as it could," GSK says. The patent covers salmeterol and fluticasone as a combined treatment for asthma. GSK expects to file an application with the patent office within several weeks, and predicts the process will take one to two years...
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
Keeping Track: Oncology Submissions From Blueprint, Y-mAbs, BMS/bluebird; Approvals For BMS’ Reblozyl, LFB’s SevenFact
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.